Bionor Immuno AS

ACTIVE

Karenslyst allé 6, Oslo, Norwaywww.bionorpharma.comSubsidiary11–50 employeesEstablished: 2000-01-01

Part of nutri pharma asa

Clinical Trials

8 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

38.5%

Phase 2

15.4%

Trial Status Distribution

Active, not recruiting

61.5%

Completed

38.5%

Clinical Trials

Trials sponsored by this organization (13)

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

Phase 1

Completed

interventional

Mar 201426 participants

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

Phase 2

Completed

interventional

Dec 201233 participants

Additional vaccination with Vacc-4x to people with HIV and responding to ART (Anti-Retroviral Therapy), who have received Vacc-4x in a previous clinical study.

Active, not recruiting

Nov 201240 participants

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Phase 1

Completed

interventional

Sep 201236 participants

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

Phase 1

Completed

interventional

Sep 201236 participants

Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical study

Active, not recruiting

Aug 201240 participants

Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical study

Phase 1

Active, not recruiting

Aug 201240 participants

Additional vaccination of Vacc-4x to people with HIV and responding to ART who have received Vacc-4x in a previous clinical study

Active, not recruiting

Aug 201240 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations